Stevens-johnson syndrome induced by combination of imatinib and allopurinol

Chemotherapy

Volumn 55, Issue 4, 2009, Pages 197-199

  Hsieh, Huei Jen ^a   Chan, Agnes L F ^a,b   Lin, Shun Jen ^b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Allopurinol; Imatinib; Stevens Johnson syndrome

Indexed keywords

ALLOPURINOL; ANTIHISTAMINIC AGENT; CORTICOSTEROID; HYDROXYUREA; IMATINIB; MEBHYDROLIN; PREDNISOLONE; PROTEIN TYROSINE KINASE INHIBITOR; URIC ACID;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CHINESE; CHRONIC KIDNEY DISEASE; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; GERIATRIC PATIENT; HUMAN; HYPERURICEMIA; PRIORITY JOURNAL; PRURITUS; SKIN BIOPSY; STEVENS JOHNSON SYNDROME; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

AGED, 80 AND OVER; ALLOPURINOL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHRONIC DISEASE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LEUKEMIA, MYELOID; PIPERAZINES; PYRIMIDINES; STEVENS-JOHNSON SYNDROME;

EID: 65549097342     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218097     Document Type: Article

References (12)

1. Brouard M, Saurat JH: Cutaneous reactions to sti571. N Engl J Med 2001;345:618-619.
2. Hung SI, Chung WH, Chen YT: HLA-B genotyping to detect carbamazepine-induced Stevens-Johnson syndrome: implications for personalizing medicine. Per Med 2005;2:225-237.
3. Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-1285.
4. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, Tulliez M, Giraudier S: Adverse cutaneous reactions to imatinib (sti571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003;48:201-206.
5. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.
6. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M: Activity of a specific inhibitor of the bcrabl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
7. Vidal D, Puig L, Sureda A, Alomar A: Sti571-induced Stevens-Johnson syndrome. Br J Haematol 2002;119:274-275.
8. Seggewiss R, Price DA, Purbhoo MA: Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update. Cytotherapy 2008;10:633-641.
9. Sevinc A: Activity of Nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case Report. Chemotherapy 2009;3;55:132-136.
10. Pavithran K, Thomas M: Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose. Indian J Dermatol Venereol Leprol 2005;71:288-289.
11. Mahapatra M, Mishra P, Kumar R: Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose. Ann Hematol 2007;86:537-538.
12. Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R: Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharma-cother 2005;39:162-164